Supriya Lifescience hosts virtual investor meeting on September 17
NiveshIQ
NSE: SUPRIYA · Healthcare
Supriya Lifescience Ltd.
₹901.75▼ ₹15.70 (-1.71%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUPRIYA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Supriya Lifescience Ltd.
Supriya Lifescience Limited, founded in 1987 and headquartered in Mumbai, specializes in the research, development, manufacture, and sale of bulk drugs and pharmaceutical chemicals across a broad portfolio that includes antihistamines, anti-asthmatics, analgesics, antihypertensives, vitamins, and oncology products. The company’s revenue for FY26 stood at ₹873 crore, with a net income of ₹198 crore, reflecting a healthy profit margin of approximately 22.7%. Recent developments include a 7% share price jump following a positive CDMO outlook for FY27, and the launch of new products such as GelHeal wound care solution and Quickblue oral cancer detection kit. Supriya’s competitive position is strengthened by its diversified API offerings and ongoing pipeline expansion into anti-depressants, ant
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹557.41 Cr +23.60% | ₹679.56 Cr +21.90% | ₹827.88 Cr +21.80% |
| EBITDA Margin | 33.23% | 39.64% | 36.91% |
| Net Profit | ₹119.11 Cr +32.60% | ₹187.96 Cr +57.80% | ₹209.12 Cr +11.30% |
| EPS | ₹14.80 | ₹23.35 | ₹25.98 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Supriya Lifescience hosts virtual investor meeting on September 17
Supriya Lifescience (NSE:SUPRIYA): What Is the Scheduled Analyst Meet on 17 Sep 2026?
🔒
+ 3 more stories about Supriya Lifescience Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹190 Cr, PAT ₹24 Cr, EPS ₹2.99, EBITDA margin 26.4%. Growth context: revenue QoQ -31.4%, PAT QoQ -67.6%. Street verdict: strong miss, revenue surprise -36.5%, PAT surprise -67.9%.
Management commentary points to order wins, deal pipeline, and backlog build and R&D investments and technology initiati...
FY26 (last completed FY): revenue ₹828 Cr, PAT ₹209 Cr, EBITDA margin 36.9%, EPS ₹25.98. Year-on-year: revenue YoY +21.8...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUPRIYA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUPRIYA alongside your other holdings
Unlock full SUPRIYA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Supriya Lifescience Ltd.?
NiveshIQ detects active intelligence signals for Supriya Lifescience Ltd. (SUPRIYA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Supriya Lifescience Ltd.?
Supriya Lifescience Ltd. operates in the Healthcare sector with a market capitalisation of ₹567,403.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.